World Sleep Industry ENCYCLOPEDIA

Passionflower Tablets

3.1.2

Product scope and botanical boundaries

Passionflower tablets combine a passionflower-derived herbal powder or extract with excipients in an immediate-release, film-coated, or other oral tablet. This entry primarily concerns the above-ground parts of Passiflora incarnata. The words “passionflower” or “Passiflora,” or a picture of passion fruit, do not identify the species or part. Passiflora edulis, which is commonly grown for edible fruit, other medicinal or ornamental Passiflora species, juice, seed oil, floral fragrance, and fruit-only extracts cannot be substituted for P. incarnata herb merely because they share a genus.

The aerial material may include leaves, stems, and flowers, and their proportions, harvest stage, and processing alter its profile. A tablet may contain powdered herb, a water extract, extracts made with different ethanol concentrations, or a proprietary standardized extract. It may also combine valerian, hops, lemon balm, melatonin, magnesium, or other nonprescription sedating ingredients. A single-ingredient study does not validate a combination, and the benefits or adverse effects of a combination cannot be assigned to passionflower alone.

Tablets, preparations, and exposure

Milligrams of herbal powder on a label cannot be converted directly into milligrams of extract. An extract should identify the full scientific name, aerial part, drug-to-extract ratio, extraction solvent, carrier, and marker range. “10:1,” “highly concentrated,” or an equivalence to a mass of fresh herb without these details is insufficient to match a research preparation. Water and different alcohol concentrations yield different mixtures, while tea, drops, capsules, and tablets have different release and exposure. Total mass does not make them interchangeable.

Tablet performance also depends on blend uniformity, compression, hardness, friability, disintegration or dissolution, coating, and storage stability. Large tablets or multi-tablet servings affect swallowing and real-world adherence. A score line indicates divisibility only when designed and validated for that purpose, and a modified-release or specially coated tablet should not be crushed to seek a faster effect. The European monograph lists several powders, liquids, and dry extracts, but all fall within a traditional-use framework based on long-standing use. It does not establish clinical equivalence among preparations or retail tablets.

Human evidence related to sleep

Human sleep evidence for passionflower is limited and varies by tea or extract, population, duration, and endpoint. In a 2011 crossover trial, 41 healthy young adults drank passionflower and placebo teas for one week each. Of six sleep-diary outcomes, only subjective sleep quality favored passionflower, and polysomnography covered just ten participants. This does not establish treatment of chronic insomnia or altered sleep architecture. The European regulator lists relief of mild mental stress and aid of sleep as traditional uses, while explicitly noting that small samples and serious design shortcomings prevented firm clinical conclusions.

A 2020 double-blind placebo-controlled trial enrolled 110 adults meeting criteria for insomnia disorder and tested a particular passionflower extract for two weeks. Polysomnographic total sleep time increased by about 23 minutes relative to placebo, narrowly reaching statistical significance. Sleep efficiency and wake after sleep onset improved within the passionflower group but were not better than placebo between groups. A separate 2024 trial of 65 people tested a proprietary aerial-part extract for 30 days and reported improvements in several subjective sleep and stress outcomes. It had no formal prospective sample-size calculation, was funded by the ingredient manufacturer, and included manufacturer employees. Both are short-term signals for defined extracts, not proof that all tablets work long term, increase deep sleep, or replace established insomnia care.

Identity, specifications, and lot quality

Identity control begins with P. incarnata, the aerial part, and a traceable cultivation lot, followed by macroscopic, microscopic, thin-layer, or liquid-chromatographic fingerprints to exclude other Passiflora species and nonconforming material. Vitexin, isovitexin, orientin, isoorientin, and related flavonoids can describe composition or process consistency. Several species may share individual flavonoids, however, so a single-marker assay does not prove species identity, and no flavonoid is an established “sleep potency unit.” Laboratory GABA or receptor findings generate hypotheses but do not replace clinical results for the finished product.

A small 2025 market study compared six food supplements with five registered herbal medicines. Five supplements failed the identity or content specifications used, whereas all five registered medicines complied. This highlights risks of label mismatch and low content but cannot represent every country or brand. Finished-product release should also cover total flavonoids and fingerprint ranges, pesticides, microorganisms, mycotoxins, elemental impurities, residual solvents, tablet weight and content uniformity, disintegration or dissolution, coating integrity, and shelf life. A test report must identify the finished product, lot, sampling, and method. “Pharmacopoeial,” “GMP,” or a branded raw material does not itself establish clinical equivalence or sleep efficacy.

Selection, trial use, and judging outcomes

Selection starts by confirming the complete species, aerial part, powder or extract, extraction solvent and ratio, amount per tablet and daily serving, every ingredient in a combination, lot, and local regulatory identity. A total “passionflower complex” weight, a fruit picture used in place of identity, or undisclosed amounts within a proprietary blend cannot be mapped to human research. Independent certification may help answer identity or contamination questions, but it does not replace evidence for insomnia efficacy.

If a clinician or pharmacist considers a short label-directed trial appropriate, a one- to two-week baseline can be recorded while wake time, light exposure, caffeine, alcohol, and other sleep aids remain stable. A diary should separately record estimated sleep onset, nighttime wakefulness, total sleep, next-day alertness, work or driving performance, and adverse effects. Feeling more relaxed is not the same endpoint as objectively longer sleep. Without a stable, meaningful benefit, increasing the tablet count, mixing sedating products, or continuing indefinitely is not appropriate. Persistent insomnia is best addressed with structured cognitive behavioral therapy for insomnia and assessment for sleep apnea, circadian disorders, medicines, pain, and mental-health contributors.

Safety, interactions, and referral boundaries

Short-term use may cause drowsiness, dizziness, and confusion or slowed thinking. Driving, cycling, or operating machinery should stop if responses are impaired. Alcohol, prescription hypnotics, anti-anxiety medicines, opioids, sedating antihistamines, and other herbs may add to central nervous system depression. “No interactions reported” in the European monograph does not mean interactions have been excluded. Anesthetics and perioperative medicines may enhance depression of the nervous system. Anyone planning surgery should tell the anesthesia and surgical teams in advance and follow professional advice for the exact product.

Passionflower should not be used during pregnancy because it may induce uterine contractions, and safety during breastfeeding is not established. The European monograph does not recommend use below age 12 because of inadequate data. Allergy, marked somnolence, persistent dizziness, or confusion warrants stopping and obtaining advice. Overdose, inability to awaken, breathing difficulty, fainting, or severe allergy requires emergency or poison-center help. Current evidence has not linked single-ingredient passionflower to clinically apparent liver injury, but every component of a combination still requires review. Loud snoring with breathing pauses, dangerous daytime sleepiness, worsening symptoms, or a mental-health crisis must not be delayed with tablets.

Regulation, supply chain, and evidence communication

Depending on jurisdiction, a passionflower tablet may be a traditional herbal medicine, nonprescription medicine, or dietary supplement. “Aid sleep” in the European monograph is a traditional-use designation based on long-standing use for mild, self-limited situations; it is not well-established use or modern confirmation of clinical efficacy. Supplement sale, manufacturing requirements, pharmacopoeial raw material, independent certification, and structure/function claims answer different questions and do not independently mean “approved to treat insomnia.”

Research communication should identify the species, aerial part, solvent and extraction ratio, proprietary preparation, population, duration, placebo, subjective or polysomnographic endpoint, and financial relationships. A single short-term difference in total sleep time must not become “falls asleep faster,” “sleeps through the night,” or “increases deep sleep.” Tea or combination-versus-drug results do not transfer to a single-ingredient tablet. Changes in cultivation region, part ratio, extraction, markers, excipients, coating, or supplier should trigger renewed fingerprint, contaminant, disintegration, and stability assessment, with somnolence, mixed use, complaints, and recalls traceable by lot.